KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Gains from Investment Securities (2016 - 2026)

Bio-Rad Laboratories has reported Gains from Investment Securities over the past 17 years, most recently at $33.3 million for Q1 2026.

  • Quarterly Gains from Investment Securities rose 321.52% to $33.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $87.0 million through Mar 2026, up 1060.0% year-over-year, with the annual reading at $61.6 million for FY2025, 1711.76% up from the prior year.
  • Gains from Investment Securities was $33.3 million for Q1 2026 at Bio-Rad Laboratories, down from $59.0 million in the prior quarter.
  • Over five years, Gains from Investment Securities peaked at $81.5 million in Q3 2023 and troughed at -$72.3 million in Q4 2024.
  • The 5-year median for Gains from Investment Securities is $13.4 million (2022), against an average of $10.7 million.
  • The largest YoY upside for Gains from Investment Securities was 49651.85% in 2022 against a maximum downside of 367.47% in 2022.
  • A 5-year view of Gains from Investment Securities shows it stood at $54.2 million in 2022, then crashed by 223.43% to -$66.9 million in 2023, then fell by 8.03% to -$72.3 million in 2024, then soared by 181.6% to $59.0 million in 2025, then tumbled by 43.56% to $33.3 million in 2026.
  • Per Business Quant, the three most recent readings for BIO's Gains from Investment Securities are $33.3 million (Q1 2026), $59.0 million (Q4 2025), and $2.5 million (Q3 2025).